Goodbye 2020, Hello 2021

China’s biotech sector has shifted from a decade of domestic involution to become a global leader in licensable drug candidates, with out-licensing deal value exceeding 100 billion yuan in H1 2026. The NewCo deal model is accelerating the trend. The critical bottleneck has shifted from R&D to cross-border business development and global clinical development executives, with demand far outpacing the limited talent pool.

China’s integrated circuit exports surged 99.5% to $216.02 billion in the first seven months of 2026, driven by booming mature-node chip production and new fab expansion. While technical engineering talent remains tight, the emerging bottleneck is global commercial and export compliance executives who can open and manage overseas markets. Demand for these roles has far outpaced the small candidate pool, with search mandates climbing alongside export figures.

China's electrolyzer exports surged 17-fold in H1 2026, with the country now holding ~60% of global manufacturing capacity. Hardware cost is no longer the bottleneck of the global green hydrogen buildout. The critical constraint is now scarce cross-functional talent that can turn export orders into fully operating, financed overseas projects, combining technical, commercial, finance and local compliance expertise.

AI executive compensation has rapidly repriced across 18‑months. Most corporate compensation committees still apply legacy general‑engineering salary bands and lose candidates to faster‑adjusting competitors.